Low Ferritin in Men on TRT: Why It Happens, When It Matters, and How to Fix It

A practical guide for men whose ferritin runs low while hemoglobin and hematocrit sit at the high end of normal. This combines discussion from the ExcelMale community with the underlying clinical research.

Important: This article is educational and is not medical advice. Iron is one of the few nutrients the body cannot easily excrete, so over-supplementing carries real risk. Any change to a TRT protocol, donation schedule, or iron intake should be made with a physician and guided by lab work, not symptoms alone.

---

1. Why Ferritin Runs Low on TRT

Two mechanisms drive ferritin down, and both come from testosterone itself, not just from blood donation. This is why men who have never donated can still see ferritin fall after starting therapy.

Mechanism 1: Testosterone suppresses hepcidin
Hepcidin is the master iron-regulating hormone. It blocks ferroportin, the channel that releases stored iron from cells into the bloodstream. When testosterone lowers hepcidin, ferroportin stays open and stored iron is pulled out of ferritin and into red-cell production.

Mechanism 2: Testosterone speeds up red-cell production
Testosterone raises EPO and increases how much iron the body uses to build red cells. Stored iron in ferritin gets spent to make those extra cells, so ferritin drops even while hemoglobin and hematocrit climb.

How much, and how fast
In the study cited on ExcelMale, ferritin fell by an average of 32% within 3 months of starting testosterone enanthate, with no change in serum iron, transferrin, or transferrin saturation. Finasteride did not block the effect, meaning DHT is not the driver. Testosterone itself is.

Figure 1. The two pathways that lower ferritin on TRT

Trigger	What happens	Result
Testosterone lowers hepcidin	Ferroportin stays open; stored iron released into blood	Ferritin falls
Testosterone raises EPO	More red cells built; iron consumed to make them	Ferritin falls, H&H rise
Phlebotomy / donation	Each donation removes iron with the blood	Ferritin falls further (5-10 pts)

The catch-22: Many men donate blood to control high hematocrit. But each donation drains more iron, so a man can end up with high hematocrit AND rock-bottom ferritin at the same time: too high to skip the donation, too iron-depleted to safely give one.

2. Does Low Ferritin Matter If H&H Are High?

This is the central debate. The honest answer: it depends on symptoms and on the full iron panel. Low ferritin is not automatically dangerous when hemoglobin and hematocrit look good, but it is not automatically safe either.

The two viewpoints

"Doesn't matter" view	"Does matter" view
Ferritin is just a storage account. If H&H are strong, oxygen delivery is fine.	Ferritin below the functional threshold causes symptoms before anemia appears. The term is "iron deficiency without anemia."
TRT deliberately shifts iron from storage into red cells, so lower ferritin can be normal redistribution.	Muscle, brain, and thyroid also need iron. They lose access once stores empty, even with normal H&H.
Supported when serum iron and transferrin saturation stay normal.	Iron deficiency can also blunt the benefit of TRT itself, since the red-cell response is iron-dependent.

Two clinical points settle much of the debate. First, high hemoglobin and hematocrit tell you red-cell production is working; they say nothing about whether the storage pool is empty. Second, in men who were already iron-deficient, testosterone did not suppress ferritin further and the hemoglobin response was weaker and less predictable, so depleted iron can cap the response to therapy.

Figure 2. Ferritin thresholds men should know

Ferritin (ng/mL)	Status	What it means
Below ~15-20	Lab-defined deficiency	Standard labs flag this. Iron stores essentially empty.
~20-30	"Normal," often symptomatic	WHO floor is 15, but physiology studies suggest 25-30 is a better minimum.
30-50	Gray zone	Fatigue, restless legs, and hair changes can appear here even without anemia.
Above ~50	Generally adequate	Symptom risk from low iron is lower. Confirm with a full panel.

Note: the widely quoted lab range for men bottoms out near 20-24 ng/mL, but there is evidence that ferritin under 50 ng/mL can cause fatigue, restless legs, and similar symptoms. "Normal" on a lab report is not the same as "optimal."

3. How ExcelMale Members Raised Ferritin

Four approaches come up repeatedly. They do not all agree, because they chase different goals: raw absorption versus steering iron into storage.

3.1 The Vorck Protocol (fast ferritin recovery)
The forum's most-cited method for rebuilding ferritin quickly after a donation. Developed by a long-term TRT user with input from a hematologist, and reported to raise ferritin about 10 points in 3 days.

Figure 3. Vorck Protocol at a glance

Element	Detail
Iron form	Ferrous bisglycinate chelate
Dose	Three 70 mg doses in one day (initial dose must be 60 mg or higher)
Timing	9:00 AM, 3:00 PM, 8:00 PM. Spacing matters.
Duration	At least 5 consecutive days
Avoid during protocol	Vitamins C and D (they suppress hepcidin and push iron into hemoglobin instead of storage)
Estradiol target	Ideally 20-60 pg/mL
Ceiling	Do not exceed 300 mg total per day

Warning : if someone has C282Y hemochromatosis, this protocol won't work. It can be dangerous.

Why the vitamin-C timing is reversed here: Standard advice says take iron with vitamin C for absorption. The Vorck method does the opposite on purpose. A 60 mg+ loading dose spikes hepcidin, which traps iron inside cells where much of it converts to ferritin. Vitamin C and D lower hepcidin, sending iron into red cells instead, the last thing a man with high hemoglobin wants. The goal here is storage, not blood iron.

Honest limitation: The protocol restores ferritin but does not reliably lower hematocrit. One member who ran daily iron rebuilt ferritin but had to donate a month earlier. Use it for ferritin recovery, not hematocrit control.

3.2 Standard oral iron with absorption tactics
The more conventional forum advice, aimed at simple absorption rather than storage steering:

• Choose iron carefully (ferrous sulfate or ferrous gluconate).
• Take with vitamin C on an empty stomach for absorption.
• Avoid calcium supplements and antacids at the same time; they block absorption.
• Start with small doses to limit stomach upset.
• Take iron every other day rather than daily; this improves absorption and is gentler on the gut.

This conflicts with the Vorck vitamin-C timing because the two are chasing different outcomes. Pick the approach that matches the goal: raw absorption (this method) or storage-steering (Vorck).

3.3 Real-world results members reported

What a member did	What happened
325 mg iron daily + a ferritin supplement	Went from deficient to iron 81 / ferritin 80 in 4 weeks, felt fine
Continued the same dose another month	Overshot to iron 118 / ferritin 101; bronze skin tone and skin sensitivity, had to back off
Iron alone vs. iron + ferritin supplement	Iron alone did little; adding ferritin made the difference for symptoms
Aggressive 325 mg iron + vitamin C + lysine	Raised ferritin to ~40 but never subjectively felt better
Cooking in cast iron	Iron in a sauce rose from 0.6 mg to 5.7 mg per 100 g

The overshoot warning: Two members independently hit iron-overload signs (bronze skin, skin burning, feeling worse) by pushing too hard. Iron has no exit route except blood loss. Aggressive supplementation without retesting is how a man swings from deficient to overloaded. Retest before continuing.

3.4 The cleaner long-term fix: adjust the protocol
Several experienced members argued the root problem is often a TRT protocol that spikes hematocrit and forces frequent phlebotomy. Options raised: smaller, more frequent injections (daily or every other day), a modestly lower overall dose, or an ester blend that preserves peak testosterone while lowering the average. Reducing the hematocrit spike can end the donation cycle that drains ferritin in the first place, which beats fighting iron in both directions.

4. Questions to Answer Before Supplementing

These separate true iron deficiency from testosterone's normal iron redistribution, and from the non-iron causes of TRT fatigue in Section 6.

About the fatigue

• When did it start, and did it line up with a dose change, a donation, or a diet change?
• Is it constant, or does it track the injection cycle (worse at trough, better after a dose)?
• Physical exhaustion, or mental fog / low motivation / low mood? These point to different causes.
• Any restless legs, cold hands and feet, hair shedding, brittle nails, ice cravings, or breathlessness on exertion? These lean toward iron deficiency specifically.

About iron and blood status

• How low is ferritin, and what is the trend over the last 2-3 draws?
• Is he donating or getting therapeutic phlebotomy, and how often?
• Where do hemoglobin and hematocrit sit right now?
• Diet: red-meat eater, vegetarian, or vegan? A vegan diet plus a dose increase is exactly what crashed one member's ferritin.

About the TRT protocol

• Dose, ester, and frequency (once weekly vs. daily/EOD)?
• Total and free testosterone, SHBG, and estradiol?

About other fatigue drivers

• Thyroid symptoms (cold intolerance, weight change, constipation)?
• Sleep quality, snoring, or witnessed apnea?
• On finasteride, an aromatase inhibitor, or other medications?

5. Blood Tests to Order

Order a full iron panel, not ferritin alone, plus the workup for the other fatigue causes.

5.1 Core iron panel

Test	Why it matters
Ferritin	Iron stores. The headline number, but incomplete alone.
Serum iron	Iron currently circulating.
TIBC	Rises when the body is iron-hungry.
Transferrin saturation (TSAT)	The key ratio. Below ~20% supports true deficiency.
Soluble transferrin receptor (sTfR)	Rises in true tissue iron deficiency; not thrown off by inflammation the way ferritin is.

Figure 4. How to read the iron panel

Pattern	Interpretation	Supplement?
Low ferritin + TSAT <20% + high TIBC	True iron deficiency	Yes, supplementation justified
Low-normal ferritin + normal TSAT + normal serum iron	Likely T-driven redistribution	Caution, less justified and riskier with high H&H
Low ferritin + high CRP	Stores truly very low (inflammation masks it)	Investigate; treat the low iron

5.2 To rule out other causes

• CBC (hemoglobin, hematocrit, RBC, plus MCV and RDW; low MCV supports iron deficiency)
• CRP or hs-CRP (inflammation falsely raises ferritin)
• TSH, free T4, free T3 (thyroid; low ferritin can itself impair thyroid function)
• Estradiol (sensitive assay), total and free testosterone, SHBG
• Vitamin B12 and folate
• Vitamin D
• Comprehensive metabolic panel; HbA1c if not recently checked

6. Other Causes of Fatigue on TRT

Low ferritin is a common culprit but far from the only one. Men often fixate on it and miss these:

Cause	Notes
Estradiol too low	The most common overlooked cause. Over-aggressive AI use or naturally low E2 causes fatigue, joint pain, low libido, low mood.
Estradiol too high	Fatigue, water retention, brain fog at the other extreme.
Suboptimal or unstable T levels	Trough dropping too low between shots, or a dose the man simply doesn't feel good on.
Thyroid dysfunction	Mimics low-T fatigue; low iron and low thyroid often coexist.
Sleep apnea	Common in men on TRT, worsened by higher hematocrit; a major fatigue driver.
B12, folate, or vitamin D deficiency	Nutritional causes of fatigue and anemia.
Lifestyle	Overtraining, poor sleep, high stress, under-eating.
Other	Blood pressure or medication effects; HCG-related fluctuations if HCG is used.

Bottom Line

• Low ferritin on TRT is real and mechanistic. Testosterone lowers hepcidin and burns through iron stores to build red cells; donation makes it worse.
• High H&H does not rule out low iron. It only tells you red-cell production is working, not that the storage tank is full.
• Decide with the full panel, not ferritin alone. Low ferritin plus TSAT under ~20% means treat; low-normal ferritin with normal TSAT means monitor.
• If supplementing, retest. Iron overload is a real risk with no easy exit.
• The durable fix is often the protocol. Smaller, more frequent doses reduce the hematocrit spike that forces the phlebotomy that drains ferritin.

Sources: ExcelMale.com threads ("Warning for Men on TRT: Low Ferritin is Bad"; "Low ferritin doesn't matter as long as hemoglobin and hematocrit are good?"; "Iron Supplementation Protocol to Raise Ferritin FAST While on TRT: The Vorck Protocol"; "Iron Supplements: How to get the most benefits without feeling sick"; "Need suggestions for supplementing iron and ferritin?"). Clinical literature: Bachman et al., J Clin Endocrinol Metab 2010; Guo et al., Am J Physiol Endocrinol Metab 2014; Artz et al., J Clin Endocrinol Metab 2020.

 

G

Thread 'Low ferritin doesn't matter as long as hemoglobin and hematocrit are good?'

Jul 20, 2022

Hello, I have been struggling with low ferritin and high hematocrit. I've searched and read through the subject matter here and elsewhere. Some folks elsewhere are saying that low ferritin is not an issue and should be of no concern as long as other blood markers such as hemoglobin and hematocrit are in range.
Gil T, who seems knowledgeable and is popular on YouTube promotes this. The theory is that Ferritin is just a storage account and it's the other markers that are the only concern for health and well being. I would certainly like this to be true as this would eliminate my...

• gallant
• low ferritin
• Replies: 45
• Forum: Testosterone Side Effect Management

 

Vorck Protocol: Fixing High Hemoglobin or Hematocrit and Low Ferritin While on TRT

Rusfertide has been approved.

https://twitter.com/x/status/2093497753829601616

Rusfertide is a synthetic hepcidin mimetic peptide that as of August 2026 is approved (only) for Polycythemia Vera, but its uses also extend to erythrocytosis and hemochromatosis. In men on TRT, EPO raises RBCs which raises erythroferrone, which suppresses hepcidin. This is the principle driver of cellular stored iron loss (ferritin depletion). Use of Rusfertide would override erythroferrone and allow ferritin to build in TRT users. Protagonist pharma HAS BEEN told that their drug can work for this condition, but they show no response or interest in pursuing FDA approval for androgen driven secondary erythrocytosis. Because of this, don't expect insurance to pick up the cost!

 

Rusfertide (Mimrylo): FDA Approval and the TRT Off-Label Question

What Just Happened

The FDA approved Mimrylo (rusfertide) on August 28, 2026, for adults with polycythemia vera, a myeloproliferative blood cancer that overproduces red blood cells. It is the first approved treatment for polycythemia vera that mimics hepcidin, the hormone that regulates iron in the body. The approval went to Takeda Pharmaceuticals America; Protagonist Therapeutics discovered the drug.

Mechanism: by limiting the iron available to make new red blood cells, it reduces their overproduction and controls red cell levels. It's a subcutaneous peptide, administered once weekly via self-injection. Takeda said the drug will be available to patients within 48 hours of approval.

The Pivotal Data (VERIFY, Phase 3)

• 293 adults with PV who required frequent phlebotomies despite standard-of-care therapy, randomized 1:1 to Mimrylo or placebo over 32 weeks. Dosing started at 19 mg SC once weekly, titrated to keep hematocrit below 45%.
• Primary endpoint: 76.9% on Mimrylo required no phlebotomies during weeks 20–32 versus 32.9% on placebo.
• 62.6% maintained hematocrit below 45% through week 32 versus 14.4% on placebo; phlebotomies dropped to 0.5 versus 1.8.
• Safety: the most common adverse reactions were injection site reactions and anemia. In VERIFY, 15.9% of patients in the rusfertide arm developed anemia.

The TRT Off-Label Rationale

The approval doesn't change the mechanistic case, only makes it materially more real.

Testosterone raises hematocrit through two pathways: it increases EPO production, and it suppresses hepcidin, which lets iron flow freely to marrow erythroid precursors and fuels RBC production. Rusfertide acts on that same chokepoint. It binds ferroportin and triggers its degradation; less ferroportin means less iron reaching the marrow, fewer red cells, and hematocrit comes down. In TRT erythrocytosis the cause is different (exogenous testosterone suppressing hepcidin, not a JAK2 mutation), but the downstream mechanism is shared.

TRT patients are arguably a cleaner model than PV patients: the cause is exogenous and dose-adjustable, rather than clonal and autonomous.

Why It's Still Not a TRT Option

• Iron status. In PV, iron deficiency coexists with excess RBC production, so restricting iron to the marrow is therapeutic. TRT patients with normal iron stores may have a different risk profile if iron restriction goes too far.
• Anemia risk matters more. In PV, controlled hematocrit reduction is the goal, so anemia is a manageable tradeoff. In a TRT patient whose goal is energy and wellbeing, tipping into anemia is a meaningful downside.
• No protocol exists. There is no dosing data, titration protocol, or safety profile established for TRT-induced erythrocytosis. What dose, how low hematocrit can safely go, and what happens if someone stops TRT while on rusfertide are all unknown.

What the approval changes: the central caveat was always the regulatory timeline. Approval removes the first gate. A prescribable drug with an accumulating real-world safety record is exactly the condition needed for researchers to start investigating erythrocytosis in other contexts, testosterone therapy included. Off-label prescribing is now legally possible; the clinical evidence base for it still does not exist.

Practical near-term barriers: PV-orphan pricing (Takeda is projecting peak global sales of $1–2 billion and did not disclose a list price at launch, but pricing will be set to PV value, likely very high), payer restriction to the PV indication, and no TRT dosing target below the PV goal of below 45%.

Current Tools for TRT High Hematocrit (Unchanged)

The standard toolkit remains: dose reduction, more frequent smaller injections to cut peaks, therapeutic phlebotomy, formulation switch to gels/creams, ruling out sleep apnea, and hydration. Intervention is warranted rather than tolerating hematocrit persistently above 52–54%.

The Bottom Line

Rusfertide is now an approved drug that acts on the exact pathway testosterone disrupts. The mechanistic case for TRT erythrocytosis is coherent, and approval clears the regulatory gate that used to be the main barrier. What's still missing: trials in non-PV erythrocytosis, dosing guidance, and a safety profile for men with normal iron stores. For managing high hematocrit on TRT today, dose optimization and phlebotomy remain the tools.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment. Rusfertide is approved only for erythrocytosis in polycythemia vera and is not approved for TRT-induced erythrocytosis. It should not be sought for this purpose outside of a clinical trial context.

 

Rusfertide (Mimrylo): FDA Approval and the TRT Off-Label Question

What Just Happened

The FDA approved Mimrylo (rusfertide) on August 28, 2026, for adults with polycythemia vera, a myeloproliferative blood cancer that overproduces red blood cells. It is the first approved treatment for polycythemia vera that mimics hepcidin, the hormone that regulates iron in the body. The approval went to Takeda Pharmaceuticals America; Protagonist Therapeutics discovered the drug.

Mechanism: by limiting the iron available to make new red blood cells, it reduces their overproduction and controls red cell levels. It's a subcutaneous peptide, administered once weekly via self-injection. Takeda said the drug will be available to patients within 48 hours of approval.

View attachment 58123

The Pivotal Data (VERIFY, Phase 3)

• 293 adults with PV who required frequent phlebotomies despite standard-of-care therapy, randomized 1:1 to Mimrylo or placebo over 32 weeks. Dosing started at 19 mg SC once weekly, titrated to keep hematocrit below 45%.
• Primary endpoint: 76.9% on Mimrylo required no phlebotomies during weeks 20–32 versus 32.9% on placebo.
• 62.6% maintained hematocrit below 45% through week 32 versus 14.4% on placebo; phlebotomies dropped to 0.5 versus 1.8.
• Safety: the most common adverse reactions were injection site reactions and anemia. In VERIFY, 15.9% of patients in the rusfertide arm developed anemia.

The TRT Off-Label Rationale

The approval doesn't change the mechanistic case, only makes it materially more real.

Testosterone raises hematocrit through two pathways: it increases EPO production, and it suppresses hepcidin, which lets iron flow freely to marrow erythroid precursors and fuels RBC production. Rusfertide acts on that same chokepoint. It binds ferroportin and triggers its degradation; less ferroportin means less iron reaching the marrow, fewer red cells, and hematocrit comes down. In TRT erythrocytosis the cause is different (exogenous testosterone suppressing hepcidin, not a JAK2 mutation), but the downstream mechanism is shared.

TRT patients are arguably a cleaner model than PV patients: the cause is exogenous and dose-adjustable, rather than clonal and autonomous.

Why It's Still Not a TRT Option

• Iron status. In PV, iron deficiency coexists with excess RBC production, so restricting iron to the marrow is therapeutic. TRT patients with normal iron stores may have a different risk profile if iron restriction goes too far.
• Anemia risk matters more. In PV, controlled hematocrit reduction is the goal, so anemia is a manageable tradeoff. In a TRT patient whose goal is energy and wellbeing, tipping into anemia is a meaningful downside.
• No protocol exists. There is no dosing data, titration protocol, or safety profile established for TRT-induced erythrocytosis. What dose, how low hematocrit can safely go, and what happens if someone stops TRT while on rusfertide are all unknown.

What the approval changes: the central caveat was always the regulatory timeline. Approval removes the first gate. A prescribable drug with an accumulating real-world safety record is exactly the condition needed for researchers to start investigating erythrocytosis in other contexts, testosterone therapy included. Off-label prescribing is now legally possible; the clinical evidence base for it still does not exist.

Practical near-term barriers: PV-orphan pricing (Takeda is projecting peak global sales of $1–2 billion and did not disclose a list price at launch, but pricing will be set to PV value, likely very high), payer restriction to the PV indication, and no TRT dosing target below the PV goal of below 45%.

Current Tools for TRT High Hematocrit (Unchanged)

The standard toolkit remains: dose reduction, more frequent smaller injections to cut peaks, therapeutic phlebotomy, formulation switch to gels/creams, ruling out sleep apnea, and hydration. Intervention is warranted rather than tolerating hematocrit persistently above 52–54%.

The Bottom Line

Rusfertide is now an approved drug that acts on the exact pathway testosterone disrupts. The mechanistic case for TRT erythrocytosis is coherent, and approval clears the regulatory gate that used to be the main barrier. What's still missing: trials in non-PV erythrocytosis, dosing guidance, and a safety profile for men with normal iron stores. For managing high hematocrit on TRT today, dose optimization and phlebotomy remain the tools.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting or modifying any hormone therapy or medical treatment. Rusfertide is approved only for erythrocytosis in polycythemia vera and is not approved for TRT-induced erythrocytosis. It should not be sought for this purpose outside of a clinical trial context.

Rusfertide is a synthetic hepcidin mimetic peptide that as of August 2026 is approved (only) for Polycythemia Vera, but its uses also extend to erythrocytosis and hemochromatosis. In men on TRT, EPO raises RBCs which raises erythroferrone, which suppresses hepcidin. This is the principle driver of cellular stored iron loss (ferritin depletion). Use of Rusfertide would override erythroferrone and allow ferritin to build in TRT users. Protagonist pharma HAS BEEN told that their drug can work for this condition, but they show no response or interest in pursuing FDA approval for androgen driven secondary erythrocytosis. Because of this, don't expect insurance to pick up the cost!


No expert in the know would recommend such!

This needs to be stressed here before all the bros start going ape s**t!

Polycythemia Vera (PV) and exogenous testosterone-induced erythrocytosis can look very similar on a BASIC blood test since both can cause high RBCs, hemoglobin and hematocrit, but they are fundamentally different conditions at the cellular, molecular and physiological level.

They require different diagnostic approaches and different medical strategies to treat safely.

Critical points everyone needs to keep in mind here!

* Rusfertide is currently FDA-approved for erythrocytosis in adults with Polycythemia Vera (PV) it is not currently approved or indicated for testosterone-induced or other secondary erythrocytosis

* There is currently no established clinical evidence supporting the safety or efficacy of rusfertide for testosterone-induced or other forms of secondary erythrocytosis

Thread 'Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera'

Sep 28, 2025

* “Polycythemia vera represents a unique situation, where you have overproduction of red blood cells in the setting of systemic iron deficiency,” Dr. Kuykendall said. Rusfertide was designed to address this particular issue.


* The endogenous hormone hepcidin is the principal regulator of systemic iron homeostasis, controlling iron through downregulation of ferroportin, a transmembrane protein responsible for delivering iron. In iron deficiency, and in polycythemia vera, hepcidin levels are low, and iron freely flows to the bone marrow at the expense of other...

• madman
• Hct/rbc Hepcidin Mimetic Pv rusfertide
• Replies: 7
• Forum: Health & Wellness

• 

Even then there are other ways to manage high hematocrit on TRT without getting caught up on that donating too frequently merry go round!

Too many men are overmedicated on T especially from the get go!

That more T is better mentality nonsense being pushed. by all those clueless sheep is to blame here.

Thread 'High Hematocrit on TRT: practical “numbers plus action” guide'

Feb 24, 2026

How often should men on TRT check their hematocrit?​

The standard monitoring schedule includes a baseline CBC before starting TRT, a recheck at 3 to 6 weeks, another at 3 months, and then at 6 and 12 months once stable. Any dose or formulation change resets the monitoring clock, requiring a recheck 4 to 6 weeks later. Men with risk factors for elevated hematocrit (sleep apnea, smoking, COPD, or a history of clotting) should check more frequently: every 3 months until the trend is stable.




* The monitoring schedule, the intervention ladder, and the attention...

• madman
• cvd hematocrit hypogonadism t therapy
• Replies: 7
• Forum: Testosterone Side Effect Management

 

Rusfertide is a synthetic hepcidin mimetic peptide that as of August 2026 is approved (only) for Polycythemia Vera, but its uses also extend to erythrocytosis and hemochromatosis. In men on TRT, EPO raises RBCs which raises erythroferrone, which suppresses hepcidin.


No expert in the know would recommend such!

This needs to be stressed here before all the bros start going ape s**t!

Polycythemia Vera (PV) and exogenous testosterone-induced erythrocytosis can look very similar on a BASIC blood test since both can cause high RBCs, hemoglobin and hematocrit, but they are fundamentally different conditions at the cellular, molecular and physiological level.

This is the problem I wanted to avoid. The whole "they are different, therefore one treatment cannot work for both" because AI said so.

That PV and SE are different doesn't matter in THIS instance. Hepcidin is the way to override erythroferrone and prevent iron from leaving cells to be used in hemoglobin. Hepcidin will always bind to ferroportin, whether it's PV, SE, or no disease at all. Its simply how it works.

I was told what I was told by Dr. Tomas Ganz that a hepcidin minetic would work for androgen driven erythrocytosis. That's pretty much the end of the debate right there. (Ganz discovered hepcidin and erythroferrone and invented a mimetic himself that he didnt bring to market.)

I found two willing hematologists to prescribe to me. One already retired unfortunately. He was giving Rusfertide to people as part of the trial. The other, I have an appointment with next week to discuss. The issue will be out of pocket cost. I don't think I can afford this but I will see.

You can't stop the signal. I told people for 5 years and a lot of people know and will try. No different than other peptides that "we don't know if they work." BPC-157 has a LOT of people complaining about how it has no human trial data for connective tissue healing. Doesn't seem to matter though, does it. I'm in that camp. Whether Protagonist runs a trial doesn't matter to me or my hematologist.

 

This is the problem I wanted to avoid. The whole "they are different, therefore one treatment cannot work for both" because AI said so.

That PV and SE are different doesn't matter in THIS instance. Hepcidin is the way to override erythroferrone and prevent iron from leaving cells to be used in hemoglobin. Hepcidin will always bind to ferroportin, whether it's PV, SE, or no disease at all. Its simply how it works.

I was told what I was told by Dr. Tomas Ganz that a hepcidin minetic would work for androgen driven erythrocytosis. That's pretty much the end of the debate right there. (Ganz discovered hepcidin and erythroferrone and invented a mimetic himself that he didnt bring to market.)

I found two willing hematologists to prescribe to me. One already retired unfortunately. He was giving Rusfertide to people as part of the trial. The other, I have an appointment with next week to discuss. The issue will be out of pocket cost. I don't think I can afford this but I will see.

You can't stop the signal. I told people for 5 years and a lot of people know and will try. No different than other peptides that "we don't know if they work." BPC-157 has a LOT of people complaining about how it has no human trial data for connective tissue healing. Doesn't seem to matter though, does it. I'm in that camp. Whether Protagonist runs a trial doesn't matter to me or my hematologist.

Who said it would not work?

I’m well aware that Protagonist has been looking into developing oral hepcidin mimetics for the treatment of erythrocytosis and abnormal tissue iron overload.

I should have been more specific when I stated no expert in the field as I was referring specifically to the field of TRT.

Even if rusfertide has the potential to provide substantial benefit to patients with erythrocytosis or HFE-related hemochromatosis as of now this is not an approach recommended by recognized experts in the field of hormone replacement therapy for men using exogenous T.

There is currently no established clinical evidence supporting the safety or efficacy of rusfertide specifically for testosterone-induced erythrocytosis.

And even beyond rusfertide too many men jump the gun when their hematocrit is hovering just above the upper end of the reference range!

* Most current guidelines, including those from the American Urological Association and the Endocrine Society, flag hematocrit above 54% as a threshold requiring intervention. Some clinicians use 52% as a softer “watch and manage” threshold, particularly for men with additional cardiovascular risk factors.

Again there are other ways to address it without ever having to get caught up in that donating too frequently merry-go-round!

Normal Hematocrit Ranges and When to Act​

Hematocrit is expressed as a percentage. It represents how much of your blood volume is made up of red blood cells.

Reference ranges for adult men:

• Normal: 41–53% (this varies slightly by lab)
• Borderline elevated on TRT: 52–54%
• Clinically elevated (act required): above 54%

Most current guidelines, including those from the American Urological Association and the Endocrine Society, flag hematocrit above 54% as a threshold requiring intervention. Some clinicians use 52% as a softer “watch and manage” threshold, particularly for men with additional cardiovascular risk factors.

A hematocrit value alone does not tell the whole story. Hemoglobin and hematocrit move together, and a complete blood count (CBC) gives both. Normal hemoglobin for adult men is approximately 13.5–17.5 g/dL. Elevated hemoglobin and hematocrit together confirm true erythrocytosis rather than a lab artifact.


The key thresholds in practice:

These are guidelines, not absolute cutoffs. Individual patient context, including history of clotting, baseline cardiovascular health, and symptoms, always shapes the clinical decision.

Thread 'High Hematocrit on TRT: practical “numbers plus action” guide'

Feb 24, 2026

How often should men on TRT check their hematocrit?​

The standard monitoring schedule includes a baseline CBC before starting TRT, a recheck at 3 to 6 weeks, another at 3 months, and then at 6 and 12 months once stable. Any dose or formulation change resets the monitoring clock, requiring a recheck 4 to 6 weeks later. Men with risk factors for elevated hematocrit (sleep apnea, smoking, COPD, or a history of clotting) should check more frequently: every 3 months until the trend is stable.




* The monitoring schedule, the intervention ladder, and the attention...

• madman
• cvd hematocrit hypogonadism t therapy
• Replies: 7
• Forum: Testosterone Side Effect Management

Professor Michael Zitzmann

We also know hematocrit can be increased by testosterone preparations. It depends on the preparation, and we think that there is data that shows that the threshold of 52-54% should not be surpassed, and men should be controlled for the hematocrit especially in the first year of treatment every 3 months



Hematocrit & Thromboembolic Risk

* TTh increase Hematocrit - clinically relevant at >52-54%

* Recommended: Control Hematocrit every 3 months in the 1st year

Thread 'TESTOSTERONE: A SAFETY UPDATE 2025'

Nov 16, 2025

Professor Michael Zitzmann

We also know hematocrit can be increased by testosterone preparations. It depends on the preparation, and we think that there is data that shows that the threshold of 52-54% should not be surpassed, and men should be controlled for the hematocrit especially in the first year of treatment every 3 months



Hematocrit & Thromboembolic Risk

* TTh increase Hematocrit - clinically relevant at >52-54%

* Recommended: Control Hematocrit every 3 months in the 1st year

...

• madman
• cvd hypogonadism testosterone trt
• Replies: 25
• Forum: Testosterone and Men's Health Articles

3.5.6 Erythrocytosis

An elevated haematocrit is the most common adverse effect of testosterone therapy. Stimulation of erythropoiesis is a normal biological action that enhances delivery of oxygen to testosterone-sensitive tissues (e.g. striated, smooth and cardiac muscle). Any elevation above the normal range for haematocrit usually becomes evident between three and 12 months after testosterone therapy initiation. However, polycythaemia can also occur after any subsequent increase in testosterone dose, switching from topical to parenteral administration, or the development of comorbidity that are linked to an increase in haematocrit (e.g. respiratory or haematological diseases).

There is no evidence that an increase in haematocrit up to and including 54% causes any adverse effects. If haematocrit exceeds 54%, there is a testosterone-independent but weak associated rise in CV events and mortality [88, 189-191]. Any relationship is complex as these studies were based on patients with any cause of secondary polycythaemia, which included smoking and respiratory diseases. There have been no specific studies in men with only testosterone-induced erythrocytosis.

As detailed, the TRAVERSE study that included symptomatic men with hypogonadism, aged 45-80 years, who had pre-existing or high risk of CVD, showed a mild higher incidence of pulmonary embolism, a component of the adjudicated tertiary end-point of venous thromboembolic events, in the testosterone therapy than in the placebo group (0.9% vs. 0.5%) [85]. However, three previous large studies did not show any evidence that testosterone therapy is associated with an increased risk of venous thromboembolism [192, 193]. Of those, one study showed that an increased risk peaked at six months after initiation of testosterone therapy, then declined over the subsequent period [194]. In one study, venous thromboembolism was reported in 42 cases, and 40 of these had a diagnosed underlying thrombophilia (including factor V Leiden deficiency, prothrombin mutations and homocysteinuria) [195]. A meta-analysis of RCTs of testosterone therapy reported that venous thromboembolism was frequently related to underlying undiagnosed thrombophilia-hypofibrinolysis disorders [86]. In an RCT of testosterone therapy in men with chronic stable angina, there were no adverse effects on coagulation by assessment of tissue plasminogen activator or plasminogen activator inhibitor-1 enzyme activity or fibrinogen levels [196]. Similarly, another meta-analysis and systematic review of RCTs found that testosterone therapy was not associated with an increased risk of venous thromboembolism [176]. With testosterone therapy, elevated haematocrit is more likely when baseline levels are near the upper limit of normal prior to initiation. Additional risk factors for increased haematocrit during therapy include smoking and pre-existing respiratory conditions. Elevated haematocrit occurs more frequently with parenteral formulations compared to topical preparations. In line with this, a large retrospective two-arm open registry comparing long- acting testosterone undecanoate with testosterone gels found that the injectable formulation was associated with a higher risk of haematocrit levels exceeding 50%, compared to gel therapy [197]. In men with pre-existing CVD, extra caution is advised with a definitive diagnosis of hypogonadism before initiating testosterone therapy and monitoring of testosterone as well as haematocrit during treatment.

In cases of elevated haematocrit without comorbidities, acute CV or venous thromboembolism events, management can include reducing the testosterone dose, switching to a different formulation, or - if haematocrit is markedly high - performing venesection (500mL), repeated if necessary. In most cases, discontinuation of testosterone therapy is not required.

Post in thread 'Latest Labs. Slight elevation in hematocrit'

Apr 4, 2026

He was born in 74.

View attachment 56354




Wise to be cautious here seeing as you had previous cardiovascular issues/surgery and you have AFib.

As I stated in one of your older threads your baseline hematocrit 48% was already sitting near the top-end.

You need to stay on top of your diet, blood pressure, lipids, inflammatory markers, endothelial/vascular health, CBC, visceral adipose.

* Most current guidelines, including those from the American Urological Association and the Endocrine Society, flag hematocrit above 54% as a threshold requiring intervention....

• madman

 

Who said it would not work?

​

Even if rusfertide has the potential to provide substantial benefit to patients with erythrocytosis or HFE-related hemochromatosis as of now this is not an approach recommended by recognized experts in the field of hormone replacement therapy for men using exogenous T. There is currently no established clinical evidence supporting the safety or efficacy of rusfertide specifically for testosterone-induced erythrocytosis.




If we're being hyper literal then on August 27, we could have said the exact same thing about Rusfertide and Polycythemia Vera. Being hyper literal doesn't really serve our community. You can continue to wait, great. Unless someone writes the letters (which I did) and puts out material on this, which I continue to do, nothing will change. This response strikes me as profoundly odd, considering nobody even _knows_ about this drug in our community except people I've told and docs who read my page. Docs in our field didn't even refer to hepcidin or erythroferrone until very recently. I'll let you speculate about whose work they were exposed to.

"It isn't FDA approved for that" and "nobody gave me their blessing" shouldn't stop any of us from asking questions and researching.

For whatever it's worth, current urological guidelines (American and European) say to inject Cypionate and Enanthate once per week. Zero studies have been conducted in anyone, ever, of an injection regimen more than once per week of these esters. Not even injecting twice. Of course, even the PDR still has a recommended injection frequency from decades ago. We kinda know better though. As well, the FDA hasn't approved TRT for age related hypogonadism, though that's changing.

The answer's staring everyone in the face.

As an aside on the published research that shows no clear risk from elevated HCT, I agree that's what the research shows. None of it, and I do mean none, controls for phlebotomy. Yes, you read that right. That meta analysis and TRAVERSE looked for adverse events -- in populations of men who were getting phlebotomy.